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Abstract
Background:  To investigate the association of Aspartate aminotransferase (AST), Alanin
aminotranferase (ALT) and Gamma glutamyl transferase (GGT) with incident type 2 diabetes.
Methods: In a nested case-control study, AST, ALT, GGT as well as classic diabetes risk factors,
insulin and C-reactive protein (CRP) were measured in 133 non-diabetic subjects at baseline of
which 68 were cases and 65 were controls. Incident diabetes was defined by the WHO 1999
criteria. Conditional logistic regression was used to calculate the odds ratio (OR) of incident
diabetes associated with different hepatic markers. We used factor analysis for clustering of classic
diabetes risk factors.
Results: In Univariate analysis both ALT and GGT were associated with diabetes with ORs of
3.07(1.21–7.79) and 2.91(1.29–6.53) respectively. After adjustment for CRP and insulin, ALT and
GGT were still predictive of incident diabetes. When the model was further adjusted for
anthropometric, blood pressure and metabolic factors, only ALT was independently associated
with diabetes [OR = 3.18 (1.02–9.86)]. No difference was found between the area under the
receiver operating characteristic curves of the models with and without ALT (0.820 and 0.802
respectively, P = 0.4)
Conclusion: ALT is associated with incident type 2 diabetes independent of classic risk factors.
However, its addition to the classic risk factors does not improve the prediction of diabetes.
Background
In Recent years Non-Alcoholic Fatty Liver Disease
(NAFLD) has drawn much attention to itself as a patho-
genic factor of insulin resistance and type 2 diabetes mel-
litus [1]. This idea is supported by several cross-sectional
studies showing an association between NAFLD and prev-
alence of type 2 diabetes as well as features of the meta-
bolic syndrome, including dyslipidemia and abdominal
obesity, which highlight insulin resistance as an impor-
tant feature of NAFLD [2-4].
Since circulating liver enzymes including aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), and
Gamma glutamyltransferase (GGT) are commonly ele-
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vated in asymptomatic patients with NAFLD [5,6], the
prospective association between the hepatic markers and
type 2 diabetes is expected, as has been reported in many
longitudinal studies [7-12]. However, the results of these
observations are variable. For example while most of the
studies demonstrated that serum GGT predicted type 2
diabetes independent of common diabetes risk factors, a
study in Pima Indians did not [9]. Moreover, some [9-11],
but not all studies [8] have demonstrated independent
and significant associations of ALT with incident type 2
diabetes mellitus.
We aimed to investigate whether baseline serum liver
enzymes including AST, ALT and GGT were associated
with incident type 2 diabetes in non-diabetic participants
of the Tehran Lipid and Glucose Study (TLGS) independ-
ent of clinical and metabolic risk factors as well as insulin
resistance and C-reactive protein (CRP) and to see if they
improve the predictive utility of the classic risk factors for
development of type 2 diabetes.
Methods
Subjects
This was a nested case-control study among participants
of the TLGS. The TLGS is a longitudinal study in which
more than 15000 residents of the Tehran district 13 aged
more than 3 years were selected by cluster random sam-
pling method in the first phase of the study between 1999
and 2001 and were followed every 3 years for occurrence
of diabetes [13]. The current study involves 10368 indi-
viduals older than 20 years. Each participant was inter-
viewed privately after signing a written consent and was
asked about past history including cigarette smoking,
prior diagnosis and family history of diabetes and taking
of anti-diabetes medications. Physical examination
including measurement of anthropometric variables and
blood pressure as well as fasting plasma glucose (FPG)
and lipids was performed in all participants. The 75-g oral
glucose tolerance test (OGTT) was also performed in sub-
jects who did not take anti-diabetes medications.
Individuals were eligible for the current study if they were
non-diabetic in the first phase. Based on α = 0.05, β = 0.10
and the estimated difference in the mean values of AST,
ALT and GGT between cases and controls [7], the sample
size was calculated as 63 for each group. After mean fol-
low up of 3.5 years there were 188 new cases of type 2 dia-
betes of which 80 individuals were randomly selected as
cases. Diabetes was defined as FPG ≥ 7.0 and/or 2-hours
glucose ≥ 11.1 mmol/l or taking of anti-diabetic medica-
tions. For each case subject, a control subject who had
remained non-diabetic at the time of the follow-up exam-
ination of the case was selected from the baseline popula-
tion after matching for age and sex. After exclusion of
subjects with missing serum backup (n = 16, 7 cases and
9 controls) and outliers (> 3SD distribution of the log
transformed CRP and hepatic enzymes, n = 11, 5 cases
and 6 controls), finally 68 cases and 65 controls entered
into the current study.
Clinical and Laboratory examinations
Detailed description of the methods for measuring
anthropometric variables including weight, height, waist
circumference (WC) and hip circumference has been pre-
viously reported [13]. Body mass index (BMI) was calcu-
lated as weight in kilograms divided by the height in
meters squared. For calculation of waist-to-hip ratio
(WHR), WC was divided by hip circumference. Systolic
and diastolic blood pressures (SBP and DBP respectively)
were measured twice in a sitting position after 15 minutes
rest and mean of the two measurements was considered as
the participant's blood pressure.
A blood sample was drawn between 7:00 and 9:00 AM
into vacutainer tubes from all study participants after 12–
14 hours overnight fasting. For each participant, a 5 ml
serum sample was stored at -70° and was used for the
baseline measurement of inflammatory and hepatic
markers. The blood analyses of FPG and 2-hours OGTT,
after oral administration of 82.5 g glucose monohydrate
(equivalent to 75 g glucose anhydrate) solution as well as
lipid measurements were done at the TLGS research labo-
ratory on the day of blood collection. Plasma fasting and
2-hour glucose were measured using an enzymatic colori-
metric method with glucose oxidase. Triglycerides (TGs)
were assayed using enzymatic colorimetric method with
glycerol phosphate oxidase. HDL-cholesterol (HDL-C)
was measured using enzymatic calorimetric method with
cholesterol esterase and cholesterol oxidase after precipi-
tation of the apolipoprotein B-containing lipoproteins
with phosphotungestic acid. AST and ALT were analyzed
by enzymatic photometry and GGT by enzymatic calori-
metric methods and their intra- and inter assay coeffi-
cients of variation (CVs) were 2.8 and 3.8% for AST, 2.2
and 3.8% for ALT, and 2.9 and 3.0% for GGT respectively.
These analyses were performed using commercial kits
(Pars Azmon Inc., Tehran, Iran) and a Selectra 2 auto-ana-
lyzer (Vital Scientific, Spankeren, The Netherlands). The
intra and inter-assay coefficients of variation (CV) were
2.2% for glucose. For HDL-C intra and inter-assay CVs
were 0.5 and 2% respectively. We measured insulin with
the immunoenzymometric (IEMA) assay (Monobind Inc.,
Costa Mesa, USA) and the intra- and inter-assay coeffi-
cients of variation (CVs) were 9.2 and 10.3% respectively.
Homeostatic model assessment for insulin resistance
(HOMA-IR) model was used to indirectly measure insulin
resistance and was calculated as Fasting glucose (mmol/l)
× insulin (μU/l)/22.5. CRP was measured using highly
sensitive IEMA (hsCRP, Diagnostic Biochem, Ontario,
Canada) with intra- and inter-assay CVs of 7.7 and 9.7%BMC Endocrine Disorders 2008, 8:5 http://www.biomedcentral.com/1472-6823/8/5
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respectively. The IEMAs were performed by Sunrise ELISA
reader (Tecan Co. Salzburg, Austria).
Statistical analysis
Baseline characteristics of the subjects were presented as
percent and mean ± SD or median with inter-quartile
range in cases of skewed variables. To achieve normal dis-
tribution, insulin, CRP and hepatic markers were log
transformed before analysis. Chi-square and independent
sample T-tests were used for comparison of baseline char-
acteristics including hepatic markers. Bivariate Pearson
correlation was assessed between the hepatic markers and
common diabetes risk factors and CRP. Conditional logis-
tic regression analysis was used to calculate the odds ratio
(OR) with 95% confidence interval of hepatic markers
associated with incident diabetes. All the hepatic markers
were entered into the model as continuous variables and
the ORs calculated referring to the risk of diabetes per one
SD increment in them. ORs were calculated first in a uni-
variate model in which only the individual hepatic marker
was entered and then in 3 other models where HOMA-IR,
CRP and common diabetes risk factors were also entered.
To control the statistical biases, resulting from adjusting
for too many variables, and collinearity in the logistic
regression model [14] and to meet the desired outcome to
variable ratio of 10 [15], we used factor analysis to reduce
the number of classic diabetes risk factors to a smaller set
of uncorrelated variables [16]. According to the Kaiser cri-
terion [16], factors with eigen-values > 1 were retained in
the extraction step. Varimax rotation was used and the
resulting pattern was interpreted based on rotated factor
loadings > 0.4. We reported the cumulative percentage of
variance accounted for by the current and all preceding
factors. Factor scores, were calculated and entered into
models as continuous independent variables. Area under
the receiver operating characteristic curve (AUC) of the
logistic regression models was used to compare their pre-
dictive power for incident type 2 diabetes [17]. SPSS 11.5
and STATA 9.0 software packages were used for the analy-
sis and P values less than 0.05 were considered as statisti-
cally significant.
Results
There were 68 new cases with type 2 diabetes and 65 age
and sex matched controls. Table 1 show that almost all of
the measured baseline risk factors were significantly
higher in case subjects than controls except smoking sta-
tus which was comparable in cases and controls. Of par-
ticular interest, cases had higher level of insulin and CRP
than control subjects (P = 0.01 and P = 0.001 respec-
tively). AST levels were comparable between cases and
controls (P = 0.2) but baseline ALT and GGT were signifi-
cantly higher in those who developed diabetes (P = 0.01
and 0.005 respectively).
Correlations between hepatic markers and common dia-
betes risk factors are presented in table 2. Whereas AST
was not significantly correlated with any risk factor, ALT
and GGT showed moderate statistically significant posi-
tive correlation with WC, WHR, FPG, 2hPG and TGs. The
magnitude of these correlations was generally stronger for
Table 1: Baseline characteristics of subjects who did and did not develope diabetes after 3.5 years of follow-up.
Without diabetes (Controls) N = 68 With diabetes (Cases) N = 65 P value
Age (years) 47 ± 13 47 ± 12 -
Male sex (%) 43 43 -
Current and ex smokers (%) 16 28 0.1
Family history of diabetes (%) 11 42 <0.001
BMI (kg/m2) 26.8 ± 4.6 30.0 ± 4.3 <0.001
Waist (cm) 89 ± 12 97 ± 10 <0.001
Systolic blood pressure (mm/Hg) 118± 14 127± 19 0.001
Diastolic blood pressure (mm/Hg) 78± 10 82± 11 0.01
Fasting plasma glucose (mmol/l) 4.8± 0.4 5.4± 0.6 <0.001
2-hour plasma glucose (mmol/l) 5.5± 1.2 7.1± 1.9 <0.001
Triglycerides* (mmol/l) 1.6 (1.1–2.3) 2.0 (1.4–2.8) 0.001
HDL cholesterol (mmol/l) 1.1± 0.3 0.9± 0.2 0.01
Fasting serum insulin* (IU/ml) 12.4 (7.6–17.4) 14.7 (11.1–20.6) 0.01
Homeostatic model assessment for insulin resistance (HOMA-
IR)¶
2.8± 1.4 3.8± 1.7 <0.001
hs-CRP* (mg/l) 0.7 (0.3–2.0) 1.3 (0.7–2.7) 0.001
γ-glutamyl transferase* (IU/L) 16.9 (13.5–22.9) 21.3 (16.4–33.5) 0.005
Alanin aminotranferase* (IU/L) 15.5 (11.0–20.5) 19.0 (15.0–26.2) 0.01
Aspartate aminotransferase* (IU/L) 19.5 (17.0–24.5) 21.0 (18.0–27.0) 0.2
*For variables with skewed distribution, median with inter-quartile range was presented. For all other continuous variables data were presented as 
mean ± SD.
¶ HOMA-IR was calculated as fasting glucose (mmol/l) × insulin (μU/l)/22.5BMC Endocrine Disorders 2008, 8:5 http://www.biomedcentral.com/1472-6823/8/5
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GGT. GGT also showed a significant positive correlation
with CRP.
Table 3 provides the result of the factor analysis among
classic diabetes risk factors. 3 factors were interpreted as
1)Anthropometric factor including BMI, WC and WHR,
2)Blood pressure factor including SBP, DBP and 2hPG,
and 3)metabolic factor including FPG, 2hPG, log TGs and
HDL-c which together accounted for 71% of the total var-
iance.
In univariate analysis, AST was not significantly associated
with type 2 diabetes whereas ALT and GGT had significant
ORs of 3.07(1.21–7.79) and 2.91(1.29–6.53) respectively
(Table 4). After adjustment for HOMA-IR and hs-CRP,
ALT [OR: 3.62(1.37–9.53)] and GGT [OR: 2.70(1.15–
6.35)] were independently associated with type 2 diabe-
tes. When the model was adjusted for anthropometric and
blood pressure factors in addition to HOMA-IR and CRP,
the association of ALT and GGT with type 2 diabetes
remained significant (P = 0.02 and P = 0.01 respectively);
however after further adjustment for the metabolic factor,
only ALT was significantly associated with type 2 diabetes
with OR of 3.18(1.02–9.86). Comparison of the AUC of
the final model with and without ALT showed that addi-
tion of ALT did not significantly increase its predictive
power [AUC = 0.846 (95% CI: 0.765–0.927) vs.
0.863(0.788–0.938), P = 0.2].
Discussion
This is the first report in a Middle Eastern population
which adds to the information regarding the role of
hepatic markers in development of type 2 diabetes. It
demonstrates that among hepatic markers only ALT is sig-
nificantly associated with development of type 2 diabetes
independent of classic risk factors as well as markers of
whole body insulin resistance (HOMA-IR) and sub-clini-
cal inflammation (CRP). However, addition of ALT to the
previously known risk factors does not improve their pre-
dictive power for type 2 diabetes.
Table 2: Pearson correlation between hepatic markers and baseline characteristics of the subjects.
γ-glutamyl transferase Alanin aminotranferase Aspartate aminotransferase
Body mass index 0.113 0.014 -0.046
Waist circumference 0.300** 0.176 0.053
Waist-to-hip ratio 0.440** 0.276** 0.173
Systolic blood pressure 0.122 -0.062 -0.006
Diastolic blood pressure 0.168 0.022 0.104
Fasting plasma glucose 0.308** 0.200* 0.016
2-hours plasma glucose 0.108 0.312** 0.005
Fasting insulin 0.117 0.081 0.000
Triglycerides 0.263** 0.022 0.048
HDL-cholesterol -0.129 0.005 0.134
C-reactive protein 0.159* -0.084 0.013
All of the hepatic markers as well as fasting insulin, Triglycerides and C-reactive protein were log transformed before analysis.
*Correlation was significant at the 0.05 level (2-tailed).
**Correlation was significant at the 0.01 level (2-tailed).
Table 3: Factor loadings resulting from factor analysis of classic diabetes risk factors.
Factors
Anthropometric Blood pressure Metabolic
Systolic blood pressure 0.24 0.83 0.11
Diastolic blood pressure 0.18 0.85 0.06
Body mass index 0.69 0.37 0.15
Waist circumference 0.93 0.22 0.17
Waist-to-hip ratio 0.81 -0.00 0.17
Fasting glucose 0.23 0.15 0.60
2-hours glucose 0.00 0.42 0.48
Log triglycerides 0.12 0.22 0.66
HDL-cholesterol -0.17 0.32 -0.73
Cumulative % of total variance 28.3 52.1 71.0
All of the hepatic markers as well as fasting insulin, Triglycerides and C-reactive protein were log transformed before analysis. *Correlation was 
significant at the 0.05 level (2-tailed). **Correlation was significant at the 0.01 level (2-tailed).BMC Endocrine Disorders 2008, 8:5 http://www.biomedcentral.com/1472-6823/8/5
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In the current study ALT and GGT showed significant cor-
relation with WC, WHR, FPG 2hPG, and TGs which is
consistent with the results of the studies that have shown
a strong association between hepatic enzymes and various
factors related to insulin resistance and the metabolic syn-
drome [2,3].
A number of prospective studies have investigated the
association of liver markers with incident type 2 diabetes.
Although most of these studies showed that GGT was an
independent predictor of diabetes [7,8,12,18,19], few of
them adjusted for the full range of classic diabetes risk fac-
tors [12] and none adjusted for baseline 2-hour glucose, a
strong and consistent risk factor for type 2 diabetes. In a
study in Pima Indians, in which AST, ALT and GGT were
measured at baseline, only ALT predicted diabetes after
adjustment for age, sex, percent body fat and insulin sen-
sitivity [9]. In the west of Scotland coronary prevention
study [10], high ALT but not AST predicted diabetes after
adjustment for BMI, SBP, TC/HDL-C ratio, TGs and FPG.
In the Insulin resistance Atherosclerosis study (IRAS) [11],
both high ALT and AST were associated with incident dia-
betes after adjustment for full range of diabetes risk factors
in addition to the markers of insulin sensitivity. On the
other hand, in 3 recent population-based studies
[7,20,21], ALT lost its association with incident diabetes
after adjustment for either a minimum [7] or full range of
diabetes risk factors [20,21]. One possible explanation for
the variability of these observations may be explained
both in terms of insufficient understanding of the biology
of the liver enzymes and incomplete capture of their cor-
relates and confounders [1]. Ethnicity could also have
some role in this regard since separate analysis of the His-
panic and black subjects in the IRAS showed a non-signif-
icant association of liver markers with diabetes risk [11].
In the current study, GGT predicted diabetes after adjust-
ment for family history of diabetes as well as anthropo-
metric and blood pressure factors including BMI, WC,
WHR, SBP and DBP; However it lost its association with
diabetes after further adjustment for metabolic factors
including FPG, 2hPG, TGs and HDL-C, which are some of
the major components of the metabolic syndrome and
might be directly related to liver fat [1]. In fact, elevated
liver enzymes even within their normal range correlate
well with increasing hepatic fat and NAFLD [22], which is
in turn related to visceral fat deposition and general body
insulin resistance [2]. However, the fact that in the current
study both ALT and GGT were significantly associated
with incident type 2 diabetes independent of markers of
abdominal obesity and HOMA-IR (a sensitive marker of
whole body insulin resistance) may highlight the role of
hepatic insulin resistance and decline in hepatic insulin
sensitivity in the association between hepatic markers,
especially ALT, and incident type 2 diabetes [11].
It has been suggested that inflammatory markers, via their
ability to enhance de novo hepatic fatty acid synthesis and
fat accumulation, may contribute to both elevated liver
enzymes and diabetes [9,23]. Significant correlation
between GGT and CRP in the current study supports this
finding. However, the fact that adjustment for CRP had
minor effect on the association of GGT with incident type
2 diabetes may indicate that GGT might also be involved
in the pathogenesis of type 2 diabetes through non-
inflammatory mechanisms related to oxidative stress [24].
In the current study, ALT was predictive of diabetes after
adjustment for all of the classic risk factors. However, it
has been suggested that making decision about the predic-
tive utility of a particular variable for diabetes risk would
be more accurate if based on its additional utility over tra-
ditional risk factors rather than its independent associa-
tion and relative risk [25]. Hence, the conclusion that
hepatic enzymes may be useful additional measures in
identifying the population at risk of diabetes, as several
Table 4: Odds ratio of incident diabetes associated with hepatic markers in univariate models and after adjustment for other markers 
and common diabetes risk factors*.
AST ALT GGT
Odds ratio P Odds ratio P Odds ratio P
Model 1 1.96(0.64–5.95) 0.2 3.07(1.21–7.79) 0.01 2.91(1.29–6.53) 0.01
Model 2 1.27(0.47–3.42) 0.5 3.62(1.37–9.53) 0.009 2.70(1.15–6.35) 0.02
Model 3 1.56 (0.42–5.74) 0.5 3.32(1.18–9.30) 0.02 3.23 (1.32–7.92) 0.01
Model 4 1.09(0.34–3.53) 0.8 3.18(1.02–9.86) 0.04 1.93(0.73–5.04) 0.1
AST: Aspartate aminotransferase, ALT: Alanin aminotransferase, GGT: Gamma glutamyltransferase
*All the hepatic markers were log transformed before analysis. Odds ratios were calculated using backward conditional logistic regression with 
standardization to a SD of 1. Factor scores obtained from factor analysis were considered as continuous independent variables. In model 1 only the 
individual hepatic markers were entered (univariate). Model 2 was adjusted for log transformed C-reactive protein and HOMA-IR. Model 3 was 
further adjusted for family history of diabetes as well as anthropometric (waist circumference, waist-to-hip ratio and body mass index) and blood 
pressure (systolic and diastolic blood pressure and 2-hours glucose) factor scores. Model 4 was adjusted for all the variables in model 3 plus 
metabolic (Fasting and 2-hours glucose, triglycerides and HDL-cholesterol) factor score.BMC Endocrine Disorders 2008, 8:5 http://www.biomedcentral.com/1472-6823/8/5
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authors have said [10,26], must rely on appropriate statis-
tical tests like calculation of AUC of the models with and
without the particular variable. In this regards, the current
study showed that ALT does not add to the predictive
power of the model based on classic diabetes risk factors.
Our study has some limitations the first of which is small
sample size. We compensated for this limitation by reduc-
ing the number of covariates in the logistic regression
models by using factor analysis to justify the variable to
outcome ratio and to reduce the statistical bias [14,15].
The second limitation is that we did not measure baseline
markers of hepatitis B and C infection which considering
the high prevalence of these infections in Iran [27], could
have resulted in elevated liver enzymes. Alcohol con-
sumption, a known cause of the elevated enzymes, is an
unlikely confounder because of religious believes in the
Iranian population. Definition of diabetes based on FPG
and 2hPG measurement to identify undiagnosed cases,
adjusting for all of the classic diabetes risk factors and
using AUC as a measure of model discrimination are
some of the strength of the current study.
The current study suggests that although serum ALT is a
strong and independent predictor and might be involved
in the pathogenesis of type 2 diabetes, its measurement in
order to strengthen the predictive power of the classic risk
factors for development of diabetes may not be justified.
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